The clinical study will assess the safety and tolerability of escalating intratumoral doses
of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
This is a Phase 1, open-label, multicenter, dose-escalation study of intratumoral injections
of mRNA-2752 alone and in combination with intravenously administered immune checkpoint
blockade therapy in participants with histologically confirmed advanced or metastatic solid
tumor malignancies or lymphoma. The study consists of Dose Escalation and Dose Confirmation
Parts, which will occur in Arm A and Arm B, followed by a Dose Expansion Part, which will
occur in Arm B, and a Dose Exploration in Arm C as a neoadjuvant therapy for cutaneous
Participants in Arm A and in Arm B will be enrolled into the Dose Escalation Part and the
doses of mRNA-2752 will be administered in a dose escalation regimen until a maximum
tolerated dose (MTD) or a recommended dose for expansion (RDE) is identified. When the
MTD/RDE is identified, participants with solid tumors or lymphoma with visceral lesions may
be enrolled into the Dose Confirmation Part to confirm that the dose is also appropriate for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.